Drug General Information |
Drug ID |
D0RQ8R
|
Former ID |
DNC006913
|
Drug Name |
2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C20H19NO
|
Canonical SMILES |
C1=CC=C(C=C1)CCC2=CC=CC=C2OCC3=CC=CC=N3
|
InChI |
1S/C20H19NO/c1-2-8-17(9-3-1)13-14-18-10-4-5-12-20(18)22-16-19-11-6-7-15-21-19/h1-12,15H,13-14,16H2
|
InChIKey |
XVQTWFFAIBVICX-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
5-hydroxytryptamine 1A receptor |
Target Info |
Inhibitor |
[1]
|
D(2) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Serotonergic synapsehsa04015:Rap1 signaling pathway
|
Gap junction
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Alcoholism
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Dopamine receptor mediated signaling pathway
|
Nicotine pharmacodynamics pathway
|
Reactome
|
Serotonin receptors
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Serotonin HTR1 Group and FOS Pathway
|
SIDS Susceptibility Pathways
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
GPCR ligand binding
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
Genes and (Common) Pathways Underlying Drug Addiction
|
GPCR downstream signaling
|
Nicotine Activity on Dopaminergic Neurons
|
References |
REF 1 | J Med Chem. 2006 Nov 2;49(22):6607-13.Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. |